Services: Stem Cells & Exosomes

What It Is

Stem cells can both copy themselves and turn into other kinds of cell, which makes them the raw material of tissue repair. Two very different things go by the name. The first is an approved area of medicine, narrow and specific: bone marrow and blood stem-cell transplant for blood cancers, cultured limbal stem cells for a burned cornea, and a small number of cell products approved for defined conditions. The second is a marketplace of clinics selling injections for conditions the products are not approved to treat, often for thousands of dollars.

Exosomes are a newer entry in that second category, cell-free preparations sold as a step beyond stem cells. This page keeps the two apart, because the clinic market is where the documented harms and the high costs fall. It names no clinic and no dose.

Stem Cells, Exosomes, and What the Clinics Inject

1What a stem cell is

A stem cell can renew itself and become other cell types. Embryonic and certain lab-reprogrammed cells are broadly flexible. The adult cells used in most clinics, mainly mesenchymal stromal cells taken from body fat or bone marrow, are far more limited in what they can turn into.

2What the clinics inject

Direct-to-consumer clinics usually draw mesenchymal stromal cells from body fat or bone marrow, or use cells from donated cord blood, then inject them into a joint, a vein or, in some cases, the eye. The cells are frequently not characterized or standardized, so what is in the syringe varies.

3Where exosomes fit

Exosomes are tiny membrane vesicles that cells release to signal to one another. Products marketed as exosome therapy are cell-free preparations promoted as the next step beyond stem cells. They sit at an earlier and less regulated stage than the cells themselves, with no standardized way yet to measure dose or potency.

How It Works

The common stem cells behave differently from the way they are marketed. The picture sold to patients is that injected stem cells travel to a damaged area, settle in, and turn into fresh cartilage, nerve or retina to replace what was lost. For the mesenchymal stromal cells that most clinics use, that is largely not what happens. These cells rarely engraft or become new tissue after injection. Where they have an effect, it is paracrine and brief: for a short time they release signaling molecules that can dampen inflammation and act on the surrounding tissue, before the body clears them. Arnold Caplan, who named the field, has argued the cells were misnamed, because they behave as local signaling cells, not tissue-building stem cells.

Exosomes take that idea one step further by dispensing with the cell. Because much of what a mesenchymal cell does after injection is send chemical messages, the reasoning goes that the messages themselves, packaged in exosomes, could be delivered directly. It is a coherent hypothesis and an active research area, and it is early: there is no standardized method yet to define what an exosome product contains or how strong a dose is, which is much of why exosome preparations sit further from approval than the cells. For the aging biology that much of the anti-aging marketing draws on, see the biology of aging.

What Changed

The picture that circulates in clinic brochures and on social media is that stem cells and exosomes are a near-universal repair kit held back only by a slow regulator, able to regrow joints, reverse aging, and treat conditions from autism to multiple sclerosis. That stretches a specific field of medicine across a menu of conditions the products have not been shown to treat.

The accurate picture is narrower and has three parts. Regenerative medicine has a few established cures, delivered in regulated settings. It has an active research frontier, exosomes among it, that is early and unfinished. And it has a large direct-to-consumer clinic market that runs ahead of or outside the evidence and has caused documented harm. The sections below order the findings by how strong the evidence is and which way it points: the established cures sit at the top, the clinic claims and the harms below them.

Where The Research Stands

The Established Uses

The evidence here is settled. Hematopoietic stem-cell transplant rebuilds a patient's blood and immune system from blood-forming stem cells drawn from bone marrow, circulating blood or cord blood, and it is standard curative care for leukemia, lymphoma and other blood disorders, with more than fifty years of clinical use behind it. In the eye, cultured autologous limbal stem cells restored a permanent, renewing corneal surface in 76.6% of eyes across 112 patients whose corneas had been destroyed mostly by chemical or thermal burns, and the successes held over long follow-up. A small set of cell products also carries regulatory approval for specific conditions. These uses are precise, tested, and delivered in regulated settings.

The Direct-to-Consumer Market

Alongside the established uses sits a large commercial market. A 2016 survey identified hundreds of United States businesses marketing stem-cell interventions directly to consumers for a wide range of conditions, and later reviews describe a sector that kept growing and added exosome offerings. The regulatory position is that most of these products are investigational: not approved for the conditions advertised, and expected to be studied in clinical trials rather than sold as treatments. The marketing typically outruns the data, promising repair or rejuvenation for joints, aging, autism and multiple sclerosis on the strength of mechanism and testimonial.

The Documented Harms

The clinic market has a documented record of harm. It includes patients blinded after fat-derived cells were injected into both eyes for macular degeneration, bloodstream infections traced to a contaminated cord-blood product, and serious joint infections after injections at cash-based clinics. These are the harms that appear when injectable biological products are sold outside the testing and oversight that approved treatments carry.

Before any stem-cell or exosome injection sold for aging, joints, or chronic disease, get an opinion from a specialist who is not selling it, and check whether a legitimate clinical trial covers your condition.

The Orthopedic Evidence

Joints are where the clinic claims are strongest and most common. Mesenchymal stromal cells, usually from fat or bone marrow, have been tested for knee osteoarthritis in several small randomized trials, and a meta-analysis of those trials found improvement in pain and function. The signal is limited: the trials are small, they differ widely in how cells are sourced and prepared, and follow-up is short. They have not established durable superiority over cheaper standard options such as physical therapy or standard injections in adequately powered head-to-head trials. The accurate reading for a knee is a modest, preliminary benefit at a price many multiples higher than the alternatives.

Exosomes

Exosome products are the newest and least settled part of the field. As cell-free preparations of signaling vesicles, they are an active research subject, and position papers from the scientists who study extracellular vesicles describe the work of turning them into medicines as early and unfinished, held back by the lack of standardized ways to define a product and measure its dose. No exosome product is approved for the anti-aging and regenerative uses clinics advertise, and preparations sold as exosome therapy raise the same contamination concerns as the contaminated cell products.

The Research & Studies

Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.

Cancer Risk And Outcome

Bone marrow and blood stem-cell transplant cures blood cancers, standard care over fifty yearsStrong

In plain terms

Bone marrow and blood stem-cell transplant is a cure for blood cancers like leukemia, and it has been standard medical care for decades.

In detail

Hematopoietic stem-cell transplant, using blood-forming stem cells from bone marrow, circulating blood or cord blood to reconstitute the blood and immune system, is established curative therapy for leukemia, lymphoma and other blood and marrow disorders, with more than fifty years of clinical use. This is a demanding hospital treatment with significant risks of its own, and it is a specific approved use that does not extend to the aging, joint and chronic-disease injections marketed by direct-to-consumer clinics.

The study · 1

Copelan, Hematopoietic stem-cell transplantation · N Engl J Med 2006;354(17):1813-1826

Vision

Cultured limbal stem cells restored a clear corneal surface in 76.6% of eyes across 112 burn patientsModerate

In plain terms

Stem cells taken from the rim of the patient's own eye, grown in the lab and transplanted back, permanently rebuilt a clear corneal surface in about three-quarters of eyes blinded by burns.

In detail

In 112 patients with corneas destroyed mostly by chemical or thermal burns, treatment with cultured autologous limbal stem cells restored a permanent, transparent, self-renewing corneal epithelium in 76.6% of eyes, with successes stable over long-term follow-up and failures occurring within the first year. This is a specific treatment for burn-related limbal stem-cell deficiency delivered in a specialist setting, not evidence for the general regenerative injections sold by clinics, and it was an uncontrolled case series rather than a randomized trial.

The study · 1

Rama et al., Limbal stem-cell therapy and long-term corneal regeneration · N Engl J Med 2010;363(2):147-155

How it works

Injected mesenchymal cells act by brief paracrine signaling, not by becoming new tissueModerate · mixed

In plain terms

The stem cells clinics usually inject do not settle in and turn into new cartilage or nerve. At most they release signaling chemicals for a short time and are then cleared, which is not the tissue rebuilding the marketing suggests.

In detail

Mesenchymal stromal cells, the cells most clinics inject, rarely engraft or differentiate into new tissue after injection; where they act, their effect is chiefly paracrine and transient, releasing signaling molecules that modulate inflammation before the cells are cleared, which is a different action from the tissue replacement implied by their marketing. This describes the dominant understanding of adult mesenchymal stromal cells and does not extend to embryonic or reprogrammed cells, and the strength and duration of the signaling effect vary by cell source and preparation.

The study · 1

Caplan, Mesenchymal Stem Cells: Time to Change the Name! · Stem Cells Transl Med 2017;6(6):1445-1451

Joint And Arthritis Pain

Stem-cell knee injections eased pain and function modestly in four small trials of 138 patientsPreliminary

In plain terms

For arthritic knees, four small randomized trials of 138 patients pooled together show stem-cell injections modestly improve pain and function, but the studies are inconsistent and have not been shown to beat cheaper standard treatments.

In detail

A meta-analysis pooling four randomized controlled trials of adipose-derived mesenchymal stromal cell injection for knee osteoarthritis, totaling 138 patients, found improvement in pain and function at 12-month follow-up, but from small trials that varied widely in cell source and preparation and had short follow-up, and without demonstrating superiority over cheaper established options. The trials are small, heterogeneous in how cells are sourced and prepared, and short in follow-up, and none establish that these injections outperform physical therapy or standard injections that cost a fraction as much.

The study · 1

Issa et al., The role of adipose-derived mesenchymal stem cells in knee osteoarthritis: a meta-analysis of randomized controlled trials · Ther Adv Musculoskelet Dis 2022;14:1759720X221146005

Go Deeper

• The biology of aging: where regeneration and stem-cell decline sit among the hallmarks of aging, and how to read an early result against a marketed one.
• Rapamycin: another frontier where a few approved uses sit beside a large off-label market, and the same discipline of keeping them apart.
• Senolytics: a neighboring anti-aging idea with strong animal data and early human trials, useful for calibrating how far ahead marketing can run.
• Peptides: the same pattern of approved drugs alongside an unregulated injectable market.

The Chinese Medicine View

Stem cells and exosomes are products of modern cell biology, isolated and named in the twentieth and twenty-first centuries, so there is no classical Chinese entry for them. No historical text assigns them a channel, a temperature or a flavor, and no traditional formula contains them. What follows places the field against the tradition as a lens, not as evidence, and it borrows no classical claim, because none exists. Nothing here suggests any herb or formula does what a stem-cell transplant does.

The tradition does reason about the territory this field acts on. Chinese medicine centers renewal and constitutional reserve on the Kidney and its store of Jing, the essence: the deep reserve a person is born with and draws down across a lifetime, whose decline the classics describe in signs close to what modern medicine calls aging. The clinics' promise to top up that reserve and regrow what has worn away with age restates a very old wish.

The tradition also holds a caution that lands here. Building the body up, tonifying, is appropriate only when there is a true deficiency and the person can assimilate what is given; the classics warn that forcing a depleted system harder than its nature allows depletes rather than restores. A powerful, invasive intervention sold for renewal, before it is warranted or tested, is the kind of forcing the tradition treats with care.

This connects a modern field to a framework the tradition has long reasoned about; it is not a claim that Chinese medicine endorses or explains stem-cell therapy. The established uses of stem cells rest on their trials and their regulation, and the clinic offerings stand or fall on the same.

Cautions

Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.

Only a few cell products are approved; most marketed regenerative ones stay investigational

Under the regulatory framework for cell-based products, only a small number of cell therapies are approved for defined conditions, while most products marketed for regenerative and anti-aging uses are investigational and are expected to be studied in clinical trials rather than sold as treatments. The line between an approved product and an investigational one is a regulatory judgment that continues to be contested and enforced unevenly, so a product being on the market is not the same as it being approved.Marks and Gottlieb, Balancing Safety and Innovation for Cell-Based Regenerative Medicine

Hundreds of US clinics sell stem-cell and exosome injections for uses the products are not approved to treat

A 2016 survey of the United States identified hundreds of businesses marketing stem-cell interventions directly to consumers for a wide range of conditions, and subsequent reviews describe a sector that has continued to grow and to add exosome offerings, largely outside the conditions for which the products are approved. The counts come from clinic self-marketing and web presence, so the true number of businesses and what each actually offers may be undercounted or misstated, but the scale of the market is not in doubt.Turner and Knoepfler, Selling Stem Cells in the USA: Assessing the Direct-to-Consumer IndustryBrinsfield et al., The evolution and ongoing challenge of unproven cell-based interventions

Three women went from near-normal sight to blindness after fat-derived cells were injected into both eyes

Three patients suffered severe bilateral vision loss after a clinic injected autologous adipose-derived stem cells into both eyes for age-related macular degeneration; visual acuity fell from a pre-injection range of 20/30 to 20/200 down to a range of 20/200 to no light perception one year later, with complications including ocular hypertension, hemorrhagic retinopathy and retinal detachment. This is a three-patient case series, so it establishes that severe harm can occur rather than a rate, and the injection was done into both eyes on the same day, which removed any healthy eye to fall back on.Kuriyan et al., Vision Loss after Intravitreal Injection of Autologous Stem Cells for AMD

Bloodstream infections traced to a bacterially contaminated cord-blood product

Patients who received an umbilical cord blood-derived product for uses other than blood or immune reconstitution developed bloodstream infections that public health investigation traced to bacterial contamination of the product itself. This was an outbreak investigation of a specific contaminated product rather than a study of a rate across all clinics, and it reflects the contamination risk of products made and handled outside approved manufacturing.Perkins et al., Notes from the Field: Infections After Receipt of Bacterially Contaminated Umbilical Cord Blood-Derived Stem Cell Products

Serious joint infections needing surgery after intra-articular injections at cash clinics

Cases have been reported of serious joint infection requiring surgical treatment after patients received intra-articular stem-cell injections at cash-based clinics for joint complaints. These are individual case reports rather than a measured infection rate, but they document that injected products from unregulated clinics can introduce joint infection.Taliaferro et al., Cash-Based Stem-Cell Clinics: The Modern Day Snake Oil Salesman? A Report of Two Cases

No exosome product is approved, and no standard yet defines a product dose or potency

Position papers from extracellular-vesicle researchers describe the development of exosome-based therapeutics as early and unfinished, held back by the lack of standardized methods to define product identity, quantify dose and confirm potency, and no exosome product is approved for the regenerative and anti-aging uses that clinics advertise. Exosome therapeutics are a legitimate and active research field, so this describes their early developmental and regulatory status rather than a verdict on their eventual potential.Lener et al., Applying extracellular vesicles based therapeutics in clinical trials: an ISEV position paperSilva et al., Development of extracellular vesicle-based medicinal products: a position paper

Stem-cell tourism has caused serious complications, including neurological, and strips away safeguards

Critical reviews of international stem-cell tourism document serious complications in patients who travel abroad for unregulated stem-cell interventions, including neurological complications, and note the absence of the manufacturing oversight, consent standards and follow-up that regulated care provides. The evidence is drawn from reviews and reported cases rather than systematic outcome tracking, because these interventions are delivered outside the systems that would record complications, which itself is part of the risk.Lyons et al., International stem cell tourism: a critical literature review and evidence-based recommendationsJulian et al., The Growing Reality of the Neurological Complications of Global Stem Cell Tourism

Most clinic offerings are not approved treatments

A few cell products are approved for defined conditions, and hematopoietic transplant and limbal cell therapy are established care. The stem-cell and exosome injections sold for aging, joints, autism, multiple sclerosis and chronic disease are, for the most part, not approved for those uses. They are investigational products being sold as treatments, and a willingness to inject is not the same as evidence that it helps.

Injections into the eye have blinded people

Three patients lost most of their sight, going from near-normal vision to blindness, after a clinic injected fat-derived stem cells into both eyes on the same day for macular degeneration. Any offer to inject cells or exosomes into or around the eye carries the risk of severe, permanent vision loss and warrants a retinal specialist opinion first.

Contaminated products have caused serious infections

Patients who received a cord blood-derived product developed bloodstream infections traced to bacterial contamination, and joint infections have followed stem-cell injections at cash-based clinics. Products made and handled outside approved manufacturing carry a risk of contamination, and an injected infection can be limb or life threatening.

Exosome products are the least regulated

Exosome preparations sit further from approval than the cells, with no standardized way yet to define what a product contains or how strong it is. No exosome product is approved for the regenerative uses clinics advertise, and the same contamination and quality concerns that affect cell products apply.

Medical tourism removes the safeguards

Traveling abroad for stem-cell treatment can mean receiving an injection with none of the manufacturing oversight, consent standards or follow-up of regulated care, and reviews document serious complications, including neurological ones, in returning patients. A treatment unavailable at home is usually unavailable because it has not passed the testing that would make it available.

The orthopedic benefit is modest and the cost is high

For knee osteoarthritis, randomized trials suggest a modest improvement in pain and function, but the trials are small and varied, follow-up is short, and the injections have not been shown to beat cheaper standard options. Weigh a several-thousand-dollar injection against physical therapy and established care with a clinician who has no financial stake in the cell product.

Talk to a clinician outside the clinic selling it

This is education, not medical advice, and it points to no clinic. If a stem-cell or exosome treatment interests you, the useful step is a conversation with a specialist in the relevant field who is not selling the injection, and a look at whether a legitimate clinical trial exists for your condition.

Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.

Common Questions

Are stem cells real medicine or a scam?

Both descriptions point at different things, which is why the field confuses people. Hematopoietic stem-cell transplant is a cure for blood cancers and has been standard care for decades, and cultured limbal stem cells can restore a cornea destroyed by a burn. Those are approved, regulated treatments. Separately, a large market of clinics sells stem-cell and exosome injections for aging, joints and chronic disease that are not approved for those uses and are not backed by completed trials. The established uses are medicine. The clinic menu for everything else is running ahead of the evidence.

Can stem cells or exosomes reverse aging or regrow my joints?

That has not been shown. The anti-aging and joint-regrowth claims rest on how the cells are marketed rather than on what they do after injection, since the common mesenchymal cells mostly signal briefly and are cleared rather than becoming new tissue. For knee osteoarthritis, randomized trials point to a modest improvement in pain and function, but from small, varied studies with short follow-up, and without evidence of beating cheaper standard care. No completed trial shows these injections reverse aging, and exosome products are even earlier than that.

Why is stem-cell therapy so expensive if it is not approved?

The direct-to-consumer market operates largely outside the approval framework, charging cash prices in the thousands because the products are sold as services rather than as approved medicines that insurance covers and regulators police. A high price and a professional setting can look like proof of value, but they reflect a business model, not evidence. Approved uses like transplant and limbal therapy are delivered in regulated medical settings, not marketed as cash procedures for a menu of conditions.

Is it safe to get a stem-cell or exosome injection at a clinic?

The safety record includes serious harms. Three patients were blinded after eye injections at a clinic, patients developed bloodstream infections from a contaminated cord blood product, and joint infections have followed clinic injections. Injectable biological products made and handled outside approved manufacturing carry contamination risk, and injections into sensitive sites like the eye can cause permanent damage. Anyone considering one is best served by a specialist who is not selling the product and by checking for a legitimate clinical trial.